Ipsos, the global market research consulting firm’s Healthcare Service Line collaborates with various pharmaceutical, biotech, and medical device enterprises, to uniquely combine therapeutic and market expertise for the creation of customized, evidence-based research approaches that inspire better healthcare. 

This summer, Ipsos will join forces with AIMed to combat drug adherence and help improve patient outcomes. The two companies will launch a year-long study with different technology partners, medical professionals, and patients, to trial new solutions and learn more about the challenges coming from drug adherence. The Challenge will officially kick start at the upcoming AIMed Europe taking place in London between 17 and 19 September (click here to find out more). A comprehensive study result is set to release in September 2020. 

The significance of drug adherence 

According to the US’ Drug and Food Administration (FDA), drug adherence simply means “taking medications correctly”. Patients have the responsibilities to consume medications that had been formally prescribed to them by a certified physician or pharmacist. However, this is not fulfilled at all times. Some of the common barriers affecting medical adherence include: not being to pay for the intended medications; failure to believe the medication would work; unable to keep track of the complex dosing schedules, and not certain of when and how to take the medications. 

Poor adherence may interfere with disease treatment process, which in turn results in complications and lower one’s chances to recover and having a better quality of life. Indeed, based on a review published last December, in the US alone, drug nonadherence is associated with 125,000 deaths, 10% of hospitalization, and $100 billion in healthcare services every year. Likewise for the UK, up to 50% of medications in England are not taken as intended and as much as £500 million could be saved if overall improvement in drug adherence. 

As Dr. Anthony Chang, Pediatric Cardiologist, Chief Intelligence and Innovation Officer of Children’s Hospital of Orange County (CHOC) and Founder and Chairman of AIMed said, “patient adherence is one of the top concerns for clinicians who see the impact of lack of adherence every single day”. 

At the moment, patients are recommended to set a daily routine for their medication intake, to keep frequent records, use a dosing container, and discuss with physicians shall concerns and difficulties arise. With the increasing prevalence of artificial intelligence (AI) and related new technologies in healthcare, both Ipsos and AIMed believe new, better and more efficient solutions could be formed. 

How to get involved? 

The Ipsos and AIMed Drug Adherence Challenge is an open challenge to invite technology companies to submit possible drug adherence solutions to partake in this year-long study., where they will also undergo an independent technology review, receive mentorship from practicing clinicians, and to test out their devised technology first-hand among a select group of patients. 

An ethics committee making up of medical and healthcare professionals will also be set up to oversee the whole challenge and provide advisory and expert guidance. At the end of the study, Ipsos and AIM seek to produce an independent, comprehensive, data-driven report designed to move the field forward in the global problem of drug adherence. 

‘Technology potentially offers a scalable solution for behavior change solutions in patient medicine adherence. We believe that behavioral science has an important role to play in developing adherence solutions and we are excited to explore the innovative ways this can be developed and offered at scale,” said Colin Strong, Global Head of Behavioral Science, Ipsos. 

Whether you are interested in joining the Challenge, be part of the ethics committee or to be part of the mentoring team of medical professionals, please contact us by submitting your interest here or follow us on the AIMed Europe official site. We look forward to hearing from you soon! 

Author Bio
synthetic gene empathy chinese artificial intelligence data medicine healthcare ai

Hazel Tang

A science writer with data background and an interest in the current affair, culture, and arts; a no-med from an (almost) all-med family. Follow on Twitter.